• Field-based trial with 196 patients shows significant reductions in seasonal allergy symptoms
  • Efficacy of AllerT in both dose groups maintained during the second birch pollen season

EPALINGES, Switzerland, September 16, 2014 – Anergis, a company developing proprietary ultra-fast allergy vaccines, today reported positive long-term efficacy results with its lead compound AllerT, a novel birch pollen allergy vaccine.

A total of 196 patients were enrolled in the Phase IIb follow-up, double-blind, placebo-controlled, field-based clinical trial. The trial objective was to evaluate the long-term efficacy of AllerT in patients who had participated last year in the fieldbased Phase IIb trial with AllerT. Patients evaluated this year either received a placebo, AllerT 50 μg or AllerT 100 μg 18 months before the second birch pollen season. No further investigational treatment was given after the initial randomization.

Subjects who had received AllerT showed persistent, statistically significant (p<0.05) and clinically meaningful (>20% difference from placebo) reductions in the primary (combined symptom and medication score) and main secondary endpoints (quality of life score and nighttime nasal symptoms). The results were remarkably consistent across all clinical endpoints and did not show meaningful differences between Year 1 and Year 2 clinical responses. In addition, the clinical effects of both doses were very similar.

Full results of the trial will be presented at an upcoming scientific conference.

"With this trial, we have confirmed our first year efficacy results and have demonstrated that a 2-month treatment with AllerT can produce long-term clinical benefits under conditions of natural allergen exposure," said Vincent Charlon, CEO of Anergis. "The combination of these new clinical data with previously demonstrated long-lasting antibody responses strongly suggests that COP allergy vaccines have a disease-modifying effect in patients suffering from allergies.”

In 2013, Anergis had already shown that patients from the AllerT Phase IIa trial had a long-lasting elevation in allergen-specific antibodies (IgG4) until at least the fourth post-treatment season.

Contact

  • Biopôle III, Route de la Corniche 9B
    CH-1066 Epalinges
  • Email:
Top

This website uses cookies to ensure you get the best experience on our website.